In the search for biochemical markers to predict the development of ILD in RA, neither Krebs von den Lungen 6 (KL-6) nor anticarbamylated protein antibodies have demonstrated predictive value superior to that of ACPA or RF [36,37,38]. This evidence concerns the gene MUC1 and interstitial lung disease.